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Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase
that plays an important role in normal cellular processes such as
adhesion, spreading, migration, proliferation and survival. In
addition, FAK is overexpressed in a variety of cancer cells and
tumours and may play a role in the development of human
cancer. As a prelude to modelling the role of aberrant FAK sig-
nalling in the initiation of cancer, the goal of the present study
was to engineer point mutations in FAK that would enhance
enzymic activity. A number of substitutions that were reported
as activating mutations in other tyrosine kinases were introduced
into FAK. Glutamic acid substitutions for two lysine residues in
the activation loop of FAK, based upon the K650E (Lys'&!!Glu)
mutant of fibroblast-growth-factor receptor 3, were made to
create ‘SuperFAK’. Two brain-specific exons were engineered
into avian FAK to create FAK6.7. SuperFAK and, to a lesser
extent, FAK6.7, exhibited increased catalytic activity in itro
INTRODUCTION
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase,
first identified in Src-transformed fibroblasts [1]. FAK localizes
to focal adhesions through its focal-adhesion-targeting (FAT)
sequence located at the C-terminus [2]. The clustering of integrins
at focal adhesions upon engagement of their extracellular-
matrix (ECM) protein ligands results in tyrosine phosphoryl-
ation and activation of FAK [1]. In addition to adhesion,
treatment of cells with a variety of soluble factors, including G-
protein-coupled-receptor agonists and receptor protein tyrosine
kinase ligands, can also induce FAK activation [1].
Upon activation, FAK autophosphorylates on Tyr$*( [3,4],
creating a binding site for SH2-domain-containing proteins. The
p85 regulatory subunit of phosphoinositide 3-kinase (PI 3-
kinase ; ‘phosphatidylinositol 3-kinase ’), phospholipase C-γ1
(PLC-γ1), growth-factor-receptor-bound protein 7 (Grb7), and
possibly Src-homology (SH)-containing protein (Shc), bind to
phosphorylated Tyr$*( through SH2-mediated interactions [5–8].
In addition, the autophosphorylation site on FAK recruits Src-
like kinases via their SH2 domains [4]. Furthermore, FAK con-
tains a proline-rich sequence upstream of Tyr$*(, which facilitates
binding to the SH3 domain of Src and stabilization of the FAK–-
Src complex [9,10]. Once Src binds to FAK, it phosphorylates
additional tyrosine residues on FAK, including Tyr&(', Tyr&(( and
Tyr*#& [3,11]. Phosphorylation of Tyr&(' and Tyr&((, which
reside in the activation loop of FAK, lead to maximal activation
Abbreviations used: CE, chicken embryo; CHO, Chinese-hamster ovary ; ECM, extracellular matrix ; EGFR, epidermal-growth-factor receptor ; ERK,
extracellular-signal-regulated kinase ; FAK, focal adhesion kinase ; FAT, focal adhesion targeting (sequence) ; FGFR3, fibroblast-growth-factor receptor
type 3; Grb, growth-factor-receptor-bound; GST, glutathione S-transferase ; K650E, Lys650UGlu; MAPK, mitogen-activated protein kinase ; p130cas,
p130 crk-associated substrate ; PI 3-kinase, phosphoinositide 3-kinase (‘phosphatidylinositol 3-kinase ’) ; PLC-γ1, phospholipase C-γ1; PP2,
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine ; PY, phosphotyrosine ; RIPA, radioimmunoprecipitation; SH, Src homology; Shc,
Src-homology-containing protein ; SuperFAK, an activated K578E/K581E mutant of FAK; TBS, Tris-buffered saline.
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compared with wild-type FAK. The expression of SuperFAK
and FAK6.7 in fibroblasts led to hyperphosphorylation of
FAK substrates. Although the catalytic activity of SuperFAK
and FAK6.7 was largely independent of cell adhesion, tyrosine
phosphorylation of downstream substrates was adhesion-
dependent. Further, since SuperFAK exhibited the same ability
as wild-type FAK to recruit Src family kinases, tyrosine phos-
phorylation of substrates was likely due to direct phosphoryl-
ation by FAK. In addition to enhanced biochemical signalling,
SuperFAK also increased the motility of epithelial cells. Super-
FAK and FAK6.7 may be valuable molecular tools to investi-
gate the potential role of aberrant FAK signalling in human
disease.
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of FAK [3]. Phosphorylation of Tyr*#& creates a binding site
for the SH2 domain of Grb2, which may link FAK to
mitogen-activated protein kinase (MAPK) signalling ([11,12],
but see [12a]). In addition to SH2-binding sites, FAK also
contains proline-rich regions that serve as docking sites for
SH3-containing proteins, including the crk-associated protein
p130cas [13,14]. FAK can thus recruit a variety of signalling
proteins to form an intricate signalling complex.
FAK is implicated in controlling a variety of integrin-
mediated biological processes. FAK regulates turnover of focal
adhesions, apparently by regulating the activity of Rho ([15],
but see [15a] ; [16,17]). FAK also regulates cell motility.
FAK-null fibroblasts and cells expressing a dominant-negative
form of FAK show decreased migration [16,18]. Conversely,
the overexpression of FAK in Chinese-hamster ovary (CHO)
cells increases cell motility [19]. The autophosphorylation site of
FAK is required for the regulation of cell motility [19] and two
effectors, PI 3-kinase and Src kinases, have been shown to
function in the FAK-dependent regulation of cell motility [6,19].
Furthermore, p130cas has been implicated as a downstream
component of the FAK-mediated signalling pathway controlling
motility [20]. In addition to migration, FAK also plays a role in
mediating cell survival. Inhibition of FAK signalling causes cells
to undergo apoptosis [21,22]. Furthermore, a constitutively
activated FAK-containing chimaeric protein, CD2FAK, is able
to rescue cells held in suspension from undergoing anoikis [23].
Recently FAK overexpression was shown to inhibit apoptosis
# 2002 Biochemical Society
592 V. Gabarra-Niecko, P. J. Keely and M. D. Schaller
induced by other stimuli [24,25]. Roles for PI 3-kinase, p130cas
and Grb2 in FAK-mediated cell survival have been proposed
[25,26]. In addition to regulating cell survival, FAK may also
function in the positive regulation of the cell cycle by controlling
the levels of cyclin D and the cyclin-dependent kinase inhibitor
p21 [27]. Although some of the mechanisms of action are not
fully understood, FAK transduces important biological signals
following integrin-dependent cell adhesion.
Constitutively activated FAK variants have been described
previously [28,29]. However, activation has been achieved by
targeting FAK constitutively to the cell membrane. Since FAK
is not membrane-bound, these variants may have acquired novel
properties and may not fully mimic FAK. Therefore the cre-
ation of an activated mutant of FAK exhibiting proper cellular
localization is of special interest. A number of reports in the
literature describe activating point mutations in tyrosine kinases.
These include a valine-to-isoleucine mutation in the ATP-binding
pocket of the epidermal-growth-factor receptor (EGFR) [30], a
methionine-to-threonine mutation in the C-terminal lobe of the
catalytic domain of RET, Met}HGF}SFR, Ron}RMSH, and
Kit kinases [31–34], and substitution of a glutamic acid for a
lysine residue in the activation loop of the fibroblast-growth-
factor receptor type 3 (FGFR3) [35]. In the present study we
describe the construction and characterization of activated
mutants of FAK. Point mutations shown to activate other tyro-
sine kinases were engineered into FAK. In addition, the regulat-
ory tyrosine residues in the activation loop of FAK, Tyr&(' and
Tyr&((, were mutated to glutamic acid to potentially mimic their
phosphorylation. Finally, an avian version of FAK6.7, a
neuronal FAK variant with two inserts flanking the autophos-
phorylation site of FAK that exhibits high autophosphorylation
activity, was also engineered [36]. Two of the mutants,
SuperFAK (with glutamic acid for lysine substitutions in the
activation loop) and FAK6.7, exhibited elevated catalytic activity
compared with wild-type FAK. Furthermore, expression of these
mutants led to the hyperphosphorylation of the FAK substrates
tensin and paxillin as well as FAK itself. Strikingly, upon
loss of adhesion, substrate phosphorylation disappeared in
SuperFAK and FAK6.7 overexpressors, despite the fact that the
kinase activity of the mutants remained high. The increased
signalling capacity of SuperFAK and FAK6.7 occurred without
affecting FAK–Src complex formation or Src activation, impli-
cating FAK activity itself in the augmentation of downstream
signalling. In addition to enhanced biochemical signalling, the
activated mutant SuperFAK was also able to enhance biological
signals, since expression of SuperFAK increased cell motility in
T47D breast epithelial cells. These activated FAK mutants may
be powerful molecular tools for investigating the potential role of




In order to make an avian version of FAK6.7, the codons for
the 6 ($*$DEISGD$*)) and 7 (%"#KSYGIDE%")) amino acid inserts
were introduced into the avian FAK cDNA by site-directed
mutagenesis using the Altered Sites Mutagenesis Kit (Promega,
Madison, WI, U.S.A.). Mutants were identified by PCR ampli-
fication and nucleotide sequencing. The MscI–SalI fragment of
the mutated cDNA (extending from nucleotide 1178 in FAK
to the multiple cloning sequence of the vector, downstream of the
FAK stop codon) was excised from the mutagenesis vector,
pALTER, and substituted for the corresponding fragment of
wild-type FAK in pBluescript-FAK [37]. Point mutations were
engineered into the full-length avian FAK cDNA in pBluescript-
FAK [37] by oligonucleotide-directed PCR mutagenesis using
the Stratagene QuikChange kit (Stratagene, La Jolla, CA,
U.S.A.). Some mutants were initially identified by restriction
digestion. To verify the presence of the intended mutations and
that no unintended mutations were introduced during the muta-
genesis procedures, each construct was completely sequenced at
the UNC-CH Automated DNA Sequencing Facility on a model
377DNASequencer (PerkinElmer,AppliedBiosystems Division)
using the ABI PRISMTM Dye Terminator Cycle Sequencing
Ready Reaction Kit with AmpliTaq DNA Polymerase, FS
(PerkinElmer, Applied Biosystems Division). The full-length
mutant FAK cDNAs were subcloned into the replication-
competent avian retroviral vector RCAS type A. RCAS A-FAK
and RCAS B-c-Src constructs have already been described
[2,38,39].
Cells and viruses
Chicken embryo (CE) cells were harvested from 9-day-old
embryos and grown as previously described [40]. T47D breast
epithelial cells and the T47D}Tva derivatives were maintained
in RPMI 1640 (Gibco BRL, Rockville, MD, U.S.A.) supple-
mented with 10% (v}v) fetal-bovine serum (Gibco BRL),
0.2 unit}ml insulin (Gibco BRL), penicillin, streptomycin, gena-
mycin and kanamycin (Sigma, St. Louis, MO, U.S.A.). CE cells
were transfected with RCAS plasmid DNA using the -
AMINE PLUSTM reagent (Gibco BRL) following the manufac-
turer’s recommended protocol. At 7 days after transfection, cells
were lysed and FAK expression was analysed. T47D cells were
transfected with the avian retroviral receptor Tva800 cDNA
(generously given by Dr P. Bates, Department of Microbiology,
University of Pennsylvania School ofMedicine, Philadelphia, PA,
U.S.A.) [41] using the Superfect reagent (Qiagen, Valencia,
CA, U.S.A.). Cells were selected in G418-containing growth
medium and expanded as stably transfected cells. Expression of
constructs was determined by fluorescent immunolabelling using
a polyclonal antibody to the Tva receptor (generously given by
Dr P. Bates), and a secondary FITC-conjugated anti-rabbit anti-
body (Jackson Immunoresearch Laboratories Inc., West Grove,
PA, U.S.A.), followed by fluorescence analysis through flow
cytometry.
Viral stocks were made from subconfluent cultures of CE cells
10 days after transfection. The culture medium was removed,
4 ml of fresh culture medium was added, and the cells were
incubated overnight. The culture medium was collected, cells
and debris were pelleted by centrifugation, and virus-containing
supernatants were divided into portions and stored at ®70 °C.
Upon passaging T47D cells, 1 ml of virus stock was added to the
T47D cultures. At 10–14 days after infection, cells were lysed
and FAK expression was analysed.
For adhesion experiments, cells were trypsinized and washed
twice in PBS containing 0.5 mg}ml soybean trypsin inhibitor
(Sigma). Cells were resuspended in serum-free medium and kept
in suspension for 45 min at 37 °C. Suspended cells were then col-
lected and lysed or plated at a concentration of 2.5¬10& cells}ml
on fibronectin-coated dishes (50 µg}ml) for the indicated times
prior to lysis [41a].
Protein analysis
Cells were lysed in modified radioimmunoprecipitation (RIPA)
buffer containing protease and phosphatase inhibitors as
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previously described [42]. The protein concentration of the
lysates was determined using the bicinchoninic acid (‘BCA’)
assay (Pierce, Rockford, IL, U.S.A.).
For immunoprecipitations, 0.3–1 mg of cell lysate was incu-
bated with primary antibody on ice for 1 h. The polyclonal FAK
antibody BC4, monoclonal tensin antibody 5B9 (generously
given by Dr Tom Parsons, Department of Microbiology, Uni-
versity of Virginia Health Sciences Center, Charlottesville, VA,
U.S.A.), Fyn antiserum (kindly given by Dr Andre! Veillette,
Laboratory of Molecular Oncology, Institut de Recherches,
Cliniques de Montreal, Montreal, PQ, Canada), the monoclonal
Src antibody EC10 (generously given by Dr Sally Parsons,
Department of Microbiology, University of Virginia Health
Sciences Center, Charlottesville, VA, U.S.A.), paxillin and
p130cas antibodies (Transduction Laboratories, Lexington, KY,
U.S.A.) were used for immunoprecipitations. Immune complexes
were precipitated with Protein A–Sepharose beads (Sigma) or
rabbit anti-mouse IgG (Jackson Immunoresearch Laboratories)
pre-bound to Protein A–Sepharose beads (Sigma) at 4 °C for 1 h.
The immune complexes were then washed twice with modified
RIPA buffer, and twice with Tris-buffered saline (TBS; 10 mM
Tris}150 mM NaCl, pH 7.0). Immune complexes were denatured
and dissociated from beads by boiling in Laemmli sample buffer
[43]. The samples were then resolved by SDS}PAGE on an 8%
gel, and analysed by Western blotting. Nitrocellulose membranes
were blocked with TBS-T (10 mM Tris}150 mM NaCl, pH 7.0,
containing 0.1% Tween 20) containing 5% (w}v) powdered
milk or with TBS-T alone when using the RC20 phosphotyrosine
antibody or with TBS-T containing 2% fish gelatin (Sigma) at
4 °C overnight when using the [PTyr$*(]FAK phosphospecific
antibody. Membranes were incubated with primary antibody in
blocking solution for 1 h at room temperature. The antibodies
described above were used for Western blotting. For detection
of phosphotyrosine, horseradish peroxidase-conjugated RC20
(Transduction Laboratories) or polyclonal [PTyr$*(]FAK,
[Tyr%"']Src and [Tyr&#(]Src phosphospecific antibodies (BioSource
International, Camarillo, CA, U.S.A.) were used. Membranes
were incubated overnight at 4 °C when using the [PTyr$*(]FAK
phosphospecific antibody. Primary antibodies were detected
using horseradish peroxidase conjugated to Protein A or anti-
mouse IgG and enhanced chemiluminescence (ECL2 ; Amersham
Pharmacia Biotech, Piscataway, NJ, U.S.A.).
In vitro kinase assays
For in itro kinase reactions, FAK or Src immune complexes
were washed twice in modified RIPA buffer, twice with TBS and





] or enolase kinase buffer [20 mM Pipes
(pH 7.2)}10 mM MgCl
#
}1 mM dithiothreitol]. For enolase
kinase assays, 5 µg of acid-denatured enolase (Sigma) was added
to each reaction mixture. For treatments with 4-amino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d ]pyrimidine (PP2), either
0.5 µM PP2 (Calbiochem, San Diego, CA, U.S.A.) or vehicle
(DMSO; Fisher Scientific, Pittsburgh, PA, U.S.A.) alone were
added to the kinase buffer. The immune complexes were then
incubated in kinase buffer and 10 µCi of [γ-$#P]ATP (Dupont–
NEN, Wilmington, DE, U.S.A.) at room temperature for the
times indicated. The kinase reactions were stopped by boiling in
Laemmli sample buffer [43]. The reactions were subjected to
SDS}PAGE. The gels were fixed in 7% acetic acid and 20%
methanol and dried. $#P incorporation was visualized by auto-
radiography and PhosphorImager analysis using the Storm860
instrument (Molecular Dynamics, Sunnyvale, CA, U.S.A.).
In vitro binding assays
The glutathione S-transferase (GST) fusion proteins were ex-
pressed in Escherichia coli and purified as described in [43a].
Briefly, expression was induced by the addition of 0.1 mM
isopropyl 1-thio-β--galactopyranoside and incubation at 37 °C
for 2 h. The bacteria were harvested and lysed by sonication in
1% Triton X-100 in PBS containing protease inhibitors (1 mM
PMSF, 0.5 mMEDTA, pH 8.0, 10 µg}ml leupeptin and 10 µg}ml
aprotinin). Clarified supernatants were incubated with GSH–
agarose beads (Sigma) for 1 h at 4 °C, washed, and finally
resuspended in an equal volume of PBS. The fusion proteins were
analysed by SDS}PAGE and Coomassie Blue staining.
Approx. 0.5–1 mg of protein lysate was pre-cleared by incuba-
tion with GST immobilized on GSH–Sepharose beads for 1 h at
4 °C. For GST–Grb2SH2 pulldowns, cells were treated overnight
with 50 µM sodium orthovanadate before lysing. The cleared
lysates were then incubated with 2 µg of GST alone or GST–SH2
domain fusion proteins immobilized on GSH–Sepharose beads
for 2 h at 4 °C. The beads were washed twice with modified
RIPA buffer and twice with TBS. The bound proteins were
denatured and eluted from the beads by boiling in Laemmli
sample buffer [43] and analysed by Western blotting.
Motility
Motility assays were performed as described previously [44]. The
underside of 12 mm-diameter transwell chambers with a 12-µm-
pore-size polycarbonate membrane (Costar, Cambridge, MA,
U.S.A.) were coated with 0.6 ml of 40 µg}ml rat tail collagen I
(Collaborative Biomedical Products, Bedford, MA, U.S.A.) for
6 h at 37 °C. The lower chamber was washed twice and filled
with serum-free RPMI 1640 medium. T47D cells were trypsin-
ized, counted, and resuspended in RPMI 1640 medium supple-
mented with 5 mg}ml BSA (Sigma) to a total concentration
of 3¬10' cells}ml. Then 1.5¬10' cells were added to the top
chamber of the transwell. The T47D cells were allowed to
migrate for 20–22 h at 37 °C. Cells remaining on the top of the
polycarbonate membrane were removed. Cells that had migrated
to the underside of the membrane were stained with DiffQuick
(Baxter, Miami, FL, U.S.A.). The cells were counted across two
diameters, a total of ten fields, each on duplicate membranes. A
mixed model test as well as paired and unpaired Student t tests
were performed using the SASTM (Cary, NC, U.S.A.) software to
identify statistically significant differences in average fold change
of motility.
RESULTS
A number of mutations known to activate tyrosine kinases were
engineered into avian FAK (Figure 1). The Y576E (Tyr&('U
Glu)}Y577E, V436I and M589T mutations had no effect on the
kinase activity of FAK or signalling downstream of FAK (results
not shown) and thus were not further characterized. The K578E}
K581E mutant, referred to as SuperFAK, and the alternatively
spliced neuronal form, FAK6.7, exhibited elevated catalytic
activity and were more extensively characterized.
SuperFAK has increased catalytic activity compared with
wild-type FAK
SuperFAK and FAK6.7 were subcloned into the RCAS A re-
troviral vector and expressed in CE cells. Western blotting of CE
cell lysates with a polyclonal FAK antibody revealed that wild-
type FAK, SuperFAK and FAK6.7 were expressed at equal levels
(Figure 2A). The altered electrophoretic mobility of FAK6.7
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Figure 1 Construction of activated mutants of FAK
(A) The sequence of the activation loop of the kinase domain of FAK is shown. In SuperFAK
two lysine residues, Lys578 and Lys581 (large Ks with diagonal numbers at the top) were
substituted with glutamic acids (E), mimicking the activating K650E mutation in FGFR3
[53]. Y576E/Y577E represents an additional mutant in which the regulatory tyrosine residues
(Tyr576 and Tyr577) in the activation loop of FAK (bold Ys with diagonal numbers at the base)
were mutated to glutamic acid (E). (B) A schematic diagram of FAK is shown. Proline-rich
regions (white Ps on mid-grey background), sites of tyrosine phosphorylation (grey Ys on a
white background) and the FAT (white ‘ FAT ’ on grey) sequence are shown. Two additional FAK
mutants were engineered to mimic activating point mutations in EGFR (V436I ; vertical white
circles) [30] and RET, Met/HGF/SFR, Ron/RMSH, and Kit kinases (M589T ; vertical
black circles) [31–34]. (C) FAK6.7, an alternatively spliced neuronal form of FAK [36], contains
two additional exons (6 and 7 ; grey boxes with white lettering) flanking Tyr397, the
autophosphorylation tyrosine residue on FAK.
was due to the two insertions (Figure 2A, lane 4). Immuno-
fluorescence studies demonstrated that, like wild-type FAK,
both SuperFAK and FAK6.7 localized to focal adhesions (results
not shown).
To determine the effect of the introduced mutations and
insertions on catalytic activity, FAK, SuperFAK and FAK6.7
were subjected to in itro kinase assays. The proteins were
immunoprecipitated from CE lysates and then incubated in
kinase reaction buffer for the indicated times. The kinase reac-
tions were stopped by the addition of Laemmli sample buffer
and analysed by SDS}PAGE and autoradiography [43]. Auto-
phosphorylation of endogenous FAK was not detected at this
exposure (Figure 2B; top panel ; lane 1), due to the small
amount of endogenous FAK that is recovered relative to the
exogenously expressed proteins (Figure 2B; bottom panel).
However, autophosphorylation of exogenous wild-type FAK
was readily detected (Figure 2B; top panel, lanes 2 and 3). A
significant increase in autophosphorylation activity was observed
in SuperFAK immune complexes compared with wild-type FAK
Figure 2 Expression and in vitro kinase activity
(A) Expression of FAK and the FAK mutants was detected by Western-blot analysis. At 7–10
days after transfection, lysates (25 µg) of CE cells expressing empty vector (lane 1), FAK
(lane 2), SuperFAK (lane 3) or FAK6.7 (lane 4) were Western-blotted with a FAK polyclonal
antibody, BC4. (B) The in vitro autophosphorylation activity of wild-type FAK and the FAK
mutants was determined using an immune complex kinase assay. FAK was immunoprecipitated
from CE cell lysates (0.5–1 mg) expressing vector alone (lane 1), FAK (lane 2), SuperFAK
(lane 3) or FAK6.7 (lane 4), using a polyclonal FAK antibody, BC4. The immune complexes were
incubated in kinase buffer containing [γ-32P]ATP for 3 or 10 min. The samples were subjected
to SDS/PAGE and visualized by autoradiography (top panel). The immune complexes were also
Western-blotted using a polyclonal FAK antibody, BC4, to ensure equal loading (bottom panel).
The positions of the molecular-mass markers are indicated on the left.
(Figure 2B; top panel, lanes 4 and 5). FAK6.7 also exhibited
increased autophosphorylation activity relative to wild-type
FAK, but the increase was less dramatic than that of SuperFAK
(Figure 2A, top panel, lanes 6 and 7). PhosphorImager analysis
revealed that FAK6.7 exhibited 2–5-fold higher activity than
wild-type FAK and that the activity of SuperFAK was 4–12
times greater than wild-type FAK. The immune complexes were
also Western-blotted with a polyclonal antibody to FAK to
demonstrate that equivalent levels of each FAK protein were
present in the immunoprecipitates (Figure 2B, bottom panel). It
can be concluded that the mutations introduced into SuperFAK
and FAK6.7 lead to an increase in in itro kinase activity
compared with wild-type FAK.
Increased phosphorylation of downstream cellular proteins
Since SuperFAK and FAK6.7 had increased catalytic activity
in itro, the ability of these mutants to increase FAK signal-
ling in io was investigated. Phosphotyrosine levels in CE cells
expressing wild-type FAK or the FAK mutants were used as a
measure of FAK signalling. Whole-cell lysates from CE cells
were analysed by Western blotting with a phosphotyrosine
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Figure 3 Elevated substrate phosphorylation in SuperFAK and FAK6.7 overexpressors
(A) Lysates (25 µg) of CE cells expressing empty vector (lane 1), FAK (lane 2), SuperFAK (lane 3) or FAK6.7 (lane 4) were Western-blotted with a phosphotyrosine antibody, RC20 (top panel).
The positions of the molecular-mass markers are indicated on the left. The same lysates (25 µg) were Western-blotted with a polyclonal FAK antibody, BC4, to ensure equal expression of FAK
protein (bottom panel). (B)–(E) FAK (B), tensin (C), paxillin (D) and p130cas (E) were immunoprecipitated from CE cells (0.5–1 mg) expressing vector alone (lane 1), FAK (lane 2), Super-
FAK (lane 3) or FAK6.7 (lane 4). The immune complexes were Western-blotted with a phosphotyrosine antibody, RC20 (B–E, top panels). The nitrocellulose membranes were stripped and
re-probed for FAK, tensin, paxillin and p130cas to ensure equal amounts of protein were being analysed (B–E, bottom panels).
antibody (Figure 3A). As previously described, overexpression
of wild-type FAK leads to only a slight increase in cellular
phosphotyrosine, and the major tyrosine phosphorylated band
corresponds to FAK itself [45] (Figure 3A, top panel, lane 2).
However, a striking increase in cellular phosphotyrosine was
observed in SuperFAK overexpressors, and to a lesser extent in
FAK6.7 overexpressors (Figure 3A, top panel, lanes 3 and 4). The
major phosphotyrosine-containing proteins were approx. 200,
125 and 68–75 kDa in size (Figure 3A; arrows). On the basis of
these molecular masses, and previous studies of FAK substrate
phosphorylation [45], it seemed likely that tensin, FAK and
paxillin are the major targets for enhanced phosphorylation in
these cells.
In order to verify the identity of the proteins that were
hyperphosphorylated, tensin, FAK, and paxillin were immuno-
precipitated from lysates of CE cells overexpressing wild-type
FAK or the mutant FAK proteins. The immune complexes were
analysed by Western blotting for phosphotyrosine (Figures
3B–3D, top panels). FAK immunoprecipitated from CE cells
transfected with wild-type FAK had a strong phosphotyrosine
signal compared with mock-transfected cells owing to the ex-
pression of the exogenous wild-type FAK protein (Figure 3B,
lane 2). A modest increase in the phosphorylation of the
immunoprecipitated FAK was observed when SuperFAK, and,
to a lesser extent, when FAK6.7 was expressed (Figure 3B, top
panel, lanes 3 and 4). The phosphorylation of tensin and paxillin
was slightly elevated upon expression of wild-type FAK com-
pared with mock-transfected cells, as was previously described
[45] (Figures 3C and 3D, top panels, lanes 2). The phospho-
tyrosine content of both tensin and paxillin was significantly
increased in SuperFAK-expressing cells compared with wild-
type-FAK-expressing cells (Figures 3C and 3D, top panels,
lanes 3). Although not so dramatically, FAK6.7 also caused
an elevation in the phosphotyrosine content of both tensin and
paxillin compared with wild-type FAK (Figures 3C and 3D, top
panels, lanes 4). The phosphotyrosine content of an additional
FAK substrate, p130cas, was similarly analysed. In contrast with
the observed phosphorylation differences on tensin and paxillin,
no significant change in the phosphotyrosine content of p130cas
was observed when either wild-type FAK, SuperFAK or FAK6.7
were expressed (Figure 3C, top panel). Control Western blots
verified that equal amounts of protein were being immuno-
precipitated in each case (Figures 3B–3E, bottom panels). These
observations indicate that the elevated catalytic activity exhibited
by SuperFAK and FAK6.7 is sufficient to amplify signalling
events immediately downstream of FAK. Interestingly, phos-
phorylation of some FAK-associated tyrosine-phosphorylated
proteins, i.e. paxillin, was increased, whereas phosphorylation
# 2002 Biochemical Society
596 V. Gabarra-Niecko, P. J. Keely and M. D. Schaller
of others was not, i.e. p130cas. Furthermore, the level of FAK
substrate phosphorylation in io correlated with the catalytic
activity of the kinases in itro.
Cell-adhesion-dependent regulation of SuperFAK and FAK6.7
signalling
Cell adhesion is a major stimulus regulating FAK-mediated
signal transduction. Upon cell detachment from the ECM, FAK
becomes dephosphorylated, its catalytic activity declines and
downstream signals are turned off [1]. To determine whether
SuperFAK and FAK6.7 were constitutively active and able to
send signals independent of cell adhesion, the cellular phospho-
tyrosine content was monitored in CE cells expressing wild-type
FAK or the FAK mutants. The cells were either kept in cul-
ture or held in suspension for 45 min prior to lysis. Lysates were
analysed by Western blotting with a phosphotyrosine antibody
(Figure 4A, top panel). As described above (Figure 3A), expres-
sion of SuperFAK, and, to a lesser extent, FAK6.7, increased
cellular phosphotyrosine to a higher level than wild-type FAK
in cultured cells (Figure 4A, top panel, lanes 3, 5 and 7). When
cells were detached, the cellular phosphotyrosine content was
dramatically reduced in every cell type (Figure 4A, top panel,
lanes 2, 4, 6 and 8). The level of phosphotyrosine in suspended
SuperFAK and FAK6.7 cells was similar to the level of phospho-
tyrosine in suspended mock-transfected cells (Figure 4A, top
panel, lanes 2, 6 and 8). Whole-cell lysates were also Western-
blotted for FAK to ensure equal expression of FAK protein
(Figure 4A, bottom panel). These observations indicate that the
downstream phosphorylation signals mediated by SuperFAK
and FAK6.7 are adhesion-dependent.
In itro kinase assays were performed to investigate whether
the decreased tyrosine phosphorylation observed upon loss of
adhesion in SuperFAK and FAK6.7 overexpressors was due to
a reduction in catalytic activity. FAK or the activated FAK
mutants were immunoprecipitated from cultured CE cells or cells
held in suspension. The immune complexes were incubated in
kinase reaction buffer for 5 min at room temperature. The kinase
reactions were stopped with the addition of Laemmli sample
buffer and the samples analysed by SDS}PAGE and auto-
radiography. As expected from previous studies [1], the activity
of wild-type FAK in suspended cells was decreased compared
with the activity of FAK in adherent cells (Figure 4B, top panel,
lanes 3 and 4). As shown above (Figure 2B), an elevation of the
autophosphorylation activity of SuperFAK, and to a lesser
extent FAK6.7, was observed in adherent cells (Figure 4B, top
panel, lanes 3, 5 and 7). Although the kinase activity of Super-
FAK and FAK6.7 decreased in the absence of an adhesion
Figure 4 Adhesion-mediated regulation of FAK signalling and kinase
activity
(A) The cellular phosphotyrosine content of CE cells expressing vector alone (lanes 1–2),
FAK (lanes 3–4), SuperFAK (lanes 5–6) or FAK6.7 (lanes 7–8) was analysed in cells kept in
culture (Cul ; lanes 1, 3, 5 and 7) and in cells held in suspension for 45 min (Su ; lanes 2, 4, 6
and 8). The lysates (25 µg) were Western-blotted using a phosphotyrosine antibody, RC20
(top panel). The same lysates (25 µg) were Western-blotted with a polyclonal FAK antibody,
BC4, to ensure equal expression of FAK protein (bottom panel). (B) The kinase activity of the
FAK mutants on loss of cell adhesion was analysed by using an immune-complex kinase
assay. FAK was immunoprecipitated from CE cells (0.5–1 mg) expressing empty vector (lanes 1
and 2), FAK (lanes 3 and 4), SuperFAK (lanes 5 and 6) or FAK6.7 (lanes 7and 8) using a
polyclonal FAK antibody, BC4. The immune complexes were incubated in kinase buffer
containing [γ-32P]ATP for 5 min. The samples were separated by SDS/8%-PAGE and 32P
incorporation was analysed by autoradiography (top panel). The immune complexes were
also Western-blotted with a polyclonal FAK antibody, BC4, to ensure equal amounts of
protein were being analysed (bottom panel). The positions of the molecular-mass markers
are indicated on the left.
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signal (Figure 4B, top panel, lanes 5 and 6, 7 and 8), SuperFAK
and FAK6.7 still exhibited significantly higher catalytic activity
compared with wild-type FAK (Figure 4B, top panels, lanes 4,
6 and 8). In fact, the autophosphorylation activity of SuperFAK
from suspended cells was higher than the activity of wild-type
FAK from adherent cells (Figure 4B, top panel, lanes 3 and 6).
As a control for equal FAK loading, the immunoprecipitates
were Western-blotted for FAK (Figure 4B, bottom panel). These
results indicate that SuperFAK, and to a lesser extent FAK6.7,
exhibit elevated catalytic activity in the presence or absence
of adhesion. The loss of downstream phosphotyrosine signals
in suspended cells can only be partially due to the decrease in
catalytic activity of the FAK mutants, suggesting an additional
mechanism(s) is involved in regulating tyrosine phosphorylation
of focal adhesion-associated substrates.
In order to test whether the activated FAK mutants gener-
ated enhanced responses to physiological signals, tyrosine
phosphorylation of paxillin was examined after cell adhesion
to fibronectin. Paxillin was immunoprecipitated from lysates of
cultured cells, cells kept in suspension for 45 minutes, or cells
replated on fibronectin-coated dishes. The paxillin immune
complexes were then Western-blotted with a phosphotyrosine
antibody. As above (Figure 3D), SuperFAK, and to a lesser
extent FAK6.7, increased the level of tyrosine phosphorylation
on paxillin compared with wild-type FAK in cultured cells
(Figure 5, top panel, lanes 4, 7 and 10). Upon loss of adhesion,
paxillin phosphorylation was lost regardless of which FAK
construct was expressed (Figure 5, top panel, compare Cul versus
Su). This result correlates with the previous observation of
phosphotyrosine levels in lysates of suspended cells (Figure 4A).
Fibronectin-mediated adhesion induced tyrosine phosphoryl-
ation of paxillin in all the cells (Figure 5, top panel, lanes 3, 6, 9
and 12). The level of paxillin phosphorylation was significantly
higher in cells expressing SuperFAK or FAK6.7 compared with
cells expressing wild-type FAK (Figure 5, top panel, lanes 6, 9
and 12). The immune complexeswereWestern-blotted for paxillin
in order to verify that equal amounts of protein were analysed
(Figure 5, bottom panel). These observations demonstrate that
the activated FAK mutants elevate FAK-mediated signals in
response to a physiologically relevant stimulus.
Phosphorylation status of tyrosine residues in SuperFAK
and FAK6.7
One possible mechanism through which the activated mutants
might elevate downstream signalling is by recruiting Src family
kinases into complex and}or enhancing signalling by Src fam-
ily kinases. In order to investigate the role of Src in SuperFAK
and FAK6.7 enhanced signalling, several lines of investigation
were pursued. Lysates of CE cells expressing wild-type FAK,
SuperFAK or FAK6.7 were Western-blotted with a phospho-
specific antibody against Tyr$*( (PY397), which is the Src SH2-
domain-binding site on FAK (Figure 6A, top panel). To control
for specificity, a FAK mutant with a phenylalanine-for-tyrosine
substitution at this site was used as a negative control. PY397
recognized wild-type FAK but not the Y397F mutant (Figure 6A,
lanes 2 and 3). Similar phosphorylation levels on Tyr$*( were
observed between wild-type FAK, SuperFAK and FAK6.7
(Figure 6A, top panel, lanes 2, 4 and 5). Lysates were Western-
blotted for FAK to ensure equivalent amounts of FAK protein
were analysed (Figure 6A, bottom panel). These observations
indicate that neither SuperFAK nor FAK6.7 exhibit increased
phosphorylation at Tyr$*( in io.
To analyse the ability of the activated FAK mutants to
associate with the Src SH2 domain in itro, a GST fusion protein
Figure 5 Physiological elevation of paxillin phosphorylation
The phosphorylation of the FAK substrate, paxillin, was analysed upon cell adhesion to
fibronectin. Paxillin was immunoprecipitated from CE cells (0.5–1 mg) expressing vector alone
(lanes 1–3), FAK (lanes 4–6), SuperFAK (lanes 7–9) or FAK6.7 (lanes 10–12). The cells were
either kept in culture (Cul ; lanes 1, 4, 7 and 10), held in suspension for 45 min (Su ; lanes 2, 5,
8 and 11) or allowed to re-attach to fibronectin-coated dishes for 30 min (lanes 3, 6, 9 and 12).
The paxillin immune complexes were Western-blotted with a phosphotyrosine antibody, RC20
(top panel). The nitrocellulose membranes were stripped and re-probed with a monoclonal
paxillin antibody to ensure equal amounts of paxillin were being analysed (bottom panel).
containing the SH2 domain of Src was used. GST fusion pro-
teins were incubated with cell lysates and the bound proteins were
Western-blotted to determine the amount of associated FAK. To
ensure comparable levels of FAK protein expression, whole-cell
lysates were Western-blotted for FAK (Figure 6B, bottom panel).
GST alone was used to control for non-specific FAK binding
(Figure 6B, top panel, lane 1). Similar amounts of exogenous
wild-type FAK and the activated FAK mutants bound to
GST–SrcSH2 (Figure 6B, top panel, lanes 3–5). These obser-
vations demonstrate that there were no changes in the ability of
SuperFAK or FAK6.7 to associate with Src in itro compared
with wild-type FAK and are in agreement with the results of the
PY397 Western blot (Figure 6A).
Co-immunoprecipitations were also performed to analyse
the association of Fyn with FAK in io. Fyn was immuno-
precipitated from CE cell lysates that overexpressed wild-
type FAK, SuperFAK or FAK6.7. The immune complexes
were Western-blotted for FAK (Figure 6C, top panel). The
same amount of FAK, SuperFAK and FAK6.7 were co-
immunoprecipitated with Fyn (Figure 6C, top panel, lanes 3–5).
As a control, secondary antibody was used alone in an immuno-
precipitation to demonstrate that the co-immunoprecipitation
of FAK was specific (Figure 6C, top panel, lane 1). The blots
were also stripped and reprobed for Fyn to ensure that equal
amounts of Fyn were immunoprecipitated (Figure 6C, bottom
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Figure 6 Phosphorylation of Tyr397 and FAK–Src complex formation
(A) The phosphorylation level of Tyr397 on FAK was analysed by Western blotting. Lysates (25 µg) from CE cells expressing vector alone (lane 1), FAK (lane 2), Y397F FAK (lane 3), SuperFAK
(lane 4) or FAK6.7 (lane 5) were Western-blotted with a [PTyr397]FAK phosphospecific polyclonal antibody (‘ Y397F ’ ; top panel). Y397F FAK was used as a negative control for antibody
specificity (lane 3). The nitrocellulose membrane was stripped and re-probed with a polyclonal FAK antibody, BC4, to ensure equal loading (bottom panel). (B) The association of the Src SH2 domain
with FAK in vitro was analysed. CE cells (0.5 mg) expressing vector alone (lane 2), FAK (lanes 1, 3), SuperFAK (lane 4) or FAK6.7 (lane 5) were pre-cleared with GST (20 µg) for 1 h at 4 °C. The
precleared lysates were then incubated with GST–SrcSH2 domain fusion protein (2 µg) for 2 h at 4 °C. GST alone (2 µg) was used to control for binding specificity (lane 1). Bound FAK was
detected by Western blotting with a polyclonal FAK antibody, BC4 (top panel). To ensure equal expression of the FAK constructs, the same CE lysates (25 µg), expressing the empty vector
(lane 2), FAK (lane 3), SuperFAK (lane 4), or FAK6.7 (lane 5) were Western-blotted with a polyclonal FAK antibody, BC4 (bottom panel). (C) The association between the FAK variants and Fyn
in vivo was analysed by co-immunoprecipitation. Fyn was immunoprecipitated using a polyclonal Fyn antibody from CE cell lysates (0.5 mg) expressing vector alone (lane 2), FAK (lane 3), SuperFAK
(lane 4), or FAK6.7 (lane 5). As a control for antibody specificity, the secondary antibody was used alone in an immunoprecipitation reaction with lysate of FAK expressing CE cells (lane 1). The
immune complexes were Western-blotted with a polyclonal FAK antibody (top panel). The nitrocellulose membrane was stripped and re-probed with a polyclonal Fyn antibody to ensure equal amounts
of Fyn were immunoprecipitated (bottom panel).
panel). These observations indicate that SuperFAK, FAK6.7
and wild-type FAK associate with equivalent amounts of Fyn
in io.
Two approaches were taken to determine whether Src family
kinases, in complex with FAK, were responsible for the enhanced
catalytic activity of SuperFAK in itro. First, kinase assays were
performed in the presence of the Src inhibitor PP2. FAK was
immunoprecipitated from CE lysates expressing vector alone,
FAK or SuperFAK. The immune complexes were then incubated
in kinase reaction buffer in the presence or absence of PP2 and
terminated by the addition of Laemmli sample buffer. The
samples were subject to SDS}PAGE and autoradiography. As
described above (Figure 2B), SuperFAK had increased autophos-
phorylation levels compared with wild-type FAK (Figure 7A,
lanes 3 and 5). Most importantly, the presence of PP2 had no
effect on the autophosphorylation activity of wild-type FAK or
SuperFAK (Figure 7A, lanes 3 and 4, and 5 and 6). In the second
approach, an enolase substrate kinase assay was used to measure
Src activity in FAK complexes. Immune complexes were incu-
bated in reaction buffer with acid-denatured enolase and the
samples analysed by SDS-PAGE and autoradiography. As a
control, [Phe&#(]Src immune complexes were used and shown to
prominently phosphorylate enolase (Figure 7B, lanes 1 and 10).
In the presence of 0.5 µM PP2, [Phe&#(]Src autophosphorylation
and enolase phosphorylation were significantly inhibited (results
not shown and Figure 7, lanes 1 and 2, and 10 and 11). FAK
immune complexes weakly phosphorylated enolase and Super-
FAK immune complexes induced enhanced enolase phos-
phorylation (Figure 7B, lanes 6 and 8). However, the presence of
PP2 had no effect on the phosphorylation of enolase by FAK or
SuperFAK (Figure 7B, lanes 6 and 7, and 8 and 9). This obser-
vation suggests that the weak phosphorylation of enolase by
FAK and SuperFAK immune complexes was due to FAK activ-
ity and not due to co-immunoprecipitating Src family kinase
activity. These results demonstrate that the increased activity
of SuperFAK in itro is not due to enhanced activity of
co-immunoprecipitating Src kinases.
The results of the phosphospecific-antibody Western blots, in
itro binding assays, Fyn co-immunoprecipitations and in itro
kinase assays indicate that FAK, SuperFAK and FAK6.7 are
equally phosphorylated on Tyr$*( and bind comparable amounts
of Src kinases. However, there remains the possibility that these
FAK variants might elevate Src activity in io. In order to
investigate this possibility, the activation state of Src was
examined using phosphospecific antibodies. Cell lysates were
Western-blotted with phosphospecific antibodies to Tyr%"'
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Figure 7 Effect of Src inhibition on FAK kinase activity in vitro
The effects of PP2, a pharmacological inhibitor of Src, on FAK kinase activity was monitored
using an immune complex kinase assay. (A) FAK was immunoprecipitated from CE lysates
(1 mg) expressing empty vector (lanes 1 and 2), FAK (lanes 3 and 4), or SuperFAK (lanes 5
and 6), using a polyclonal FAK antibody, BC4. The immune complexes were incubated in kinase
buffer containing [γ-32P]ATP for 8 min in the presence (­) of 0.5 µM PP2 or vehicle alone
(DMSO ; ®). (B) Src was immunoprecipitated from CE lysates (1 mg) expressing [Phe527]Src
(‘ Src527F ’), using a monoclonal Src antibody, EC10. The Src (lanes 1 and 2) and FAK (lanes
4–10) immune complexes (isolated as described in A) were incubated with 5 µg of acid-
denatured enolase in enolase kinase buffer containing [γ-32P]ATP in the presence (­) of
0.5 µM PP2 or vehicle alone (DMSO ;®) for 13 min. As a control, a FAK immune complex
was incubated in an autophosphorylation reaction in the absence of enolase (lane 3). All kinase
reaction samples were subjected to SDS/PAGE and autoradiography. The position of Src (closed
arrowhead), FAK (open arrow) and enolase (closed arrow) are indicated. An underexposure of
lanes 1 and 2 is shown in lanes 10 and 11. The positions of the molecular-mass markers are
indicated on the left. (C) The FAK immune complexes were also Western-blotted using a
polyclonal FAK antibody, BC4, to ensure equal amounts of protein were being analysed.
(PY416), which is in the activation loop of Src, or to Tyr&#(
(PY527), which is a negative regulatory site of phosphorylation.
As controls for specificity, CE cells expressing c-Src or [Phe&#(]-
Src were analysed. Under steady-state conditions, c-Src is largely
inactive, and phosphorylation of Tyr%"' is low, whereas phos-
phorylation of Tyr&#( is high. [Phe&#(]Src cannot be phosphoryl-
ated on Tyr&#(, rendering it highly active and resulting in high
phosphorylation of Tyr%"'. The phosphospecific PY416 antibody
prominently recognized [Phe&#(F]Src and weakly recognized
c-Src, suggesting that the antibody was specific to Tyr%"' (Figure
8A, top panel). The specificity of PY527 was also verified, since
this antibody recognized c-Src, but not the Y527F Src mutant
(Figure 8A, middle panel). Upon co-expression with wild-type
FAK, an increase in Tyr%"' phosphorylation was observed on
c-Src (Figure 8B, top panel, lanes 1 and 2), indicating that co-
expression with FAK can activate Src. The level of Tyr%"'
phosphorylation when SuperFAK or FAK6.7 was co-expressed
with c-Src was the same as in cells co-expressing wild-type FAK
and c-Src (Figure 8B, top panel, lanes 2–4). The level of
phosphorylation of Tyr&#( on c-Src remained unchanged, regard-
less of co-expression of FAK proteins (Figure 8B, second
panel). To monitor the amounts of protein being analysed, Src
and FAK Western blots were performed (Figure 8A, bottom
panel, and Figure 8B, third and bottom panels). The observations
indicate that wild-type FAK, SuperFAK and FAK6.7 have
similar effects on the phosphorylation of Src. Therefore the
mechanism by which SuperFAK and FAK6.7 send amplified
signals in io is not via enhanced activation of Src kinases.
The phosphorylation of Tyr*#& in the C-terminus of FAK
creates a binding site for the SH2 domain of Grb2 ([11,12],
but see [12a]). To explore phosphorylation of Tyr*#& a phospho-
specific antibody was initially used. However, under the blot-
ting conditions used, this antibody recognized a FAK mutant
with a phenylalanine substitution for Tyr*#& (results not shown),
precluding its use in this analysis. As an alternative approach,
Tyr*#& phosphorylation in SuperFAK and FAK6.7 was investi-
gated by examining the ability of the FAK mutants to associate
with the Grb2SH2 domain in itro. A GST fusion protein con-
taining the Grb2SH2 domain was incubated with vanadate-
treated lysates of CE cells expressing FAK, or the activated
FAK variants, and bound proteins analysed by Western blot-
ting for FAK. To ensure comparable levels of FAK protein
expression, whole cell lysates were Western-blotted for FAK
(Figure 9, bottom panel). FAK bound to the GST–GrbSH2
domain, but failed to associate with GST alone (Figure 9, top
panel, lanes 1 and 3). Higher levels of SuperFAK were found
associated with the Grb2 SH2 domain compared with wild-type
FAK (Figure 9, top panel, lanes 3 and 4). In contrast, similar
amounts of FAK6.7 and wild-type FAK associated with the
Grb2 SH2 domain (Figure 9, top panel, lanes 3 and 5). These
results suggest that SuperFAK has elevated phosphorylation
at Tyr*#&.
Increased motility of T47D cells expressing SuperFAK
Since SuperFAK and FAK6.7 increased FAK signalling bio-
chemically, the ability of these mutants to impinge upon FAK-
mediated biological processes was tested. In order to investigate
the effects of the activated FAK proteins on cell motility, T47D
cells, a breast-cancer epithelial cell line, were utilized. The
T47D cells were engineered to stably express the receptor for
the avian subgroup A retrovirus, Tva800 [41]. Whereas, the par-
ental T47D cells are resistant to infection with avian retroviruses
since the cells lack the viral receptor, the derived cell line, T47D}
Tva, is susceptible to infection with avian A type retroviruses.
The FAK constructs, cloned into RCAS type A, were transfected
into CE cells. Virus produced in CE cells was collected and used
to infect the T47D}Tva cells to generate populations of cells
expressing each of the FAK proteins of interest. Western blots
were performed to examine expression of FAK proteins follow-
ing infection of the T47D}Tva cells. These results demonstrated
that FAK, SuperFAK and FAK6.7 were expressed to high levels
in the T47D}Tva cells (Figure 10A).
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Figure 8 Phosphorylation status of Src in cells co-expressing FAK and Src
(A) The phosphorylation status of the activation loop tyrosine (Tyr416) and the inhibitory tail
tyrosine (Tyr527) in Src were analysed by Western blotting. In order to ensure antibody
specificity, CE cell lysates (25 µg) overexpressing c-Src (lane 1) or Src with a tyrosine-527-
to-phenylalanine substitution, [Phe527]Src (‘ Src527F ’), (lane 2) were Western-blotted with
polyclonal Src phosphospecific antibodies against phosphorylated Tyr416 (‘ PY416 ’ ; top panel)
or phosphorylated Tyr527 (‘ PY527 ’ ; middle panel). The nitrocellulose membrane was stripped
and re-probed with a monoclonal Src antibody, EC10, to ensure equal expression (bottom
panel). (B) CE cell lysates (25 µg) co-expressing c-Src and vector alone (lane 1), FAK
(lane 2), SuperFAK (lane 3) or FAK6.7 (lane 4) were Western-blotted with a Src activation-loop
phosphospecific tyrosine antibody, PY416 (top panel), or a Src inhibitory tail phosphospecific
tyrosine antibody, PY527 (second panel). The nitrocellulose membranes were stripped and
Figure 9 Phosphorylation of Tyr925 is increased in cells expressing
SuperFAK
The phosphorylation status of Tyr925 on FAK was analysed using an in vitro binding assay. CE
cells expressing empty vector (lane 2), FAK (lanes 1, 3), SuperFAK (lane 4) or FAK6.7
(lane 5) were treated overnight with vanadate (50 µM), then lysed. The CE lysates (1 mg) were
precleared with GST (20 µg) for 1 h at 4 °C. Pre-cleared lysates were then incubated with a
GST–Grb2SH2 fusion protein (lanes 2–5) or GST alone (lane 1). Bound FAK was detected by
Western blotting with a polyclonal FAK antibody, BC4 (top panel). The same lysates (25 µg)
were Western-blotted with a polyclonal FAK antibody, BC4, to ensure equal expression of the
FAK constructs (bottom panel).
Using a transwell motility assay as previously described [44],
the haptotactic motility of the cells was analysed. Populations
of infected T47D}Tva cells were allowed to migrate for 20–22 h
through a porous transwell membrane coated on the underside
with collagen I (40 µg}ml). The non-motile cells were removed
from the top of the membrane, and the cells that migrated
to the underside of the membrane were stained and counted. The
average fold change in motility was plotted (Figure 10B).
The motility of T47D cells was significantly increased by FAK
overexpression, which is consistent with previous findings
demonstrating a role for FAK in regulating motility in other cell
types [16,18,19]. Expression of SuperFAK further increased the
motility of T47D cells compared with cells expressing FAK,
whereas FAK6.7 was less efficient than wild-type FAK in en-
hancing haptotaxis. These observations demonstrate the ability
of SuperFAK to amplify a FAK-mediated biological response.
DISCUSSION
In the present study we describe the construction of two activated
mutants of FAK: SuperFAK and FAK6.7. SuperFAK, and to a
lesser extent FAK6.7, showed increased catalytic activity in itro
compared with wild-type FAK. The catalytic activity of both
re-probed with a monoclonal Src antibody, EC10 (third panel), or a polyclonal FAK antibody,
BC4 (bottom panel), to ensure equal amounts of protein were being analysed.
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Figure 10 Elevation of T47D/Tva motility in cells expressing FAK or
SuperFAK
(A) The expression of the FAK proteins in T47D/Tva cells 10 days after infection was analysed
by Western blotting. Lysates (25 µg) of T47D/Tva cells infected with the empty retroviral vector
(lane 1) or retrovirus containing the FAK (lane 2), SuperFAK (lane 3), or FAK6.7 (lane 4) cDNAs
were Western-blotted with a polyclonal FAK antibody, BC4. The positions of the molecular-mass
markers are indicated on the left. (B) The motility of T47D/Tva cells expressing empty vector
(mock), FAK, SuperFAK or FAK6.7 was measured in a transwell system. Cells were allowed
to migrate to the underside of a collagen-coated transwell membrane for 20–22 h. The number
of cells that reached the underside of the membrane were counted. The average (³S.E.M.) fold
change in migration from 11 experiments is shown. The difference in motility between FAK and
mock, and between SuperFAK and mock were statistically significant (P ! 0.05).
mutants was partially regulated by adhesion, since both exhibited
reduced catalytic activity from cells in suspension. Nevertheless,
the enzymic activity of SuperFAK from suspended cells greatly
exceeded the activity of wild-type FAK. The elevated activity of
SuperFAK and FAK6.7 translated into increased downstream
biochemical signals in io, as demonstrated by the phosphoryl-
ation of FAK substrates, i.e. paxillin and tensin. Despite the
high level of catalytic activity of SuperFAK in suspended cells,
phosphorylation of downstream substrates by SuperFAK, as
well as FAK6.7, was dependent on adhesion. The expression
of the activated FAK mutants in CE cells had no effect on cell
morphology, and their subcellular localization was identical with
that of wild-type FAK (results not shown). Furthermore, the
elevation of the FAK signal upon SuperFAK expression leads to
increased motility of breast-cancer cells. Thus the activated
mutant of FAK, SuperFAK, may be a powerful tool that can be
used to study the consequences of increased and}or aberrant
FAK signalling in a variety of physiological contexts.
In many protein kinases, phosphorylation of residues in the
activation loop, analogous to Tyr&(' and Tyr&(( in FAK, is a
mechanism of enzyme activation [46]. The negative charge intro-
duced by the phosphate groups stabilizes the active conforma-
tion, in which the ATP and the substrate-binding sites of the
kinase domain are accessible [46]. In the case of the Y576E}
Y577E FAK mutant, no change in catalytic activity or down-
stream tyrosine phosphorylation signals was observed. It was
expected that the introduction of the charged residues might
mimic phosphorylation of the tyrosine residues, which normally
enhances the catalytic activity of FAK [3]. However, it appears
that the tyrosine-to-glutamic acid substitutions in Y576E}Y577E
were not sufficient to cause the conformational change necessary
for the activation of FAK. Interestingly, although substitutions
of acidic residues for activation loop phosphorylation sites can
activate some protein kinases, e.g. MAPK}extracellular-signal-
related kinase (ERK) kinase (‘MEK’) [46], there are no reports
of mutational activation of tyrosine kinases using this strategy.
In the case of SuperFAK, the double substitution of the
activation-loop lysine residues (Lys&() and Lys&)") with glutamic
acid residues did lead to activation of the kinase, whereby cata-
lytic activity was elevated and downstream biochemical and
cellular events were augmented. Thus the substitution of acidic
residues for basic residues in the activation loop results in cata-
lytic activation, as originally reported for FGFR3 [35]. The
negatively charged glutamic acid residues may alter the conform-
ation in such a way as to mimic the conformational change
that occurs when the regulatory tyrosine residues in the acti-
vation loop of FAK are phosphorylated. Alternatively, the
activation of SuperFAK could be explained by an increase
in the level of phosphorylation of the regulatory tyrosine
residues in the kinase domain of FAK, Tyr&(' and Tyr&((.
The double lysine- to-glutamic acid substitution may alter the
recognition of FAK by either a tyrosine kinase, likely Src, or
a tyrosine phosphatase resulting in elevated phosphorylation of
Tyr&(' and Tyr&((, leading to enhanced activity.
FAK6.7 is an avian version of an alternatively spliced variant
of FAK found in rat brain [36]. As previously reported, FAK6.7
has elevated autophosphorylation activity in itro [36,48]. In
addition, we have shown that this mutant can also elevate
tyrosine phosphorylation of substrates in io. The mechanism of
activation of the mutant is not clear. It has been speculated that
alterations around the autophosphorylation site might alter the
level of phosphorylation at that site. It has been reported that
FAK6.7 expressed in COS-7 cells does exhibit elevated phos-
phorylation at Tyr$*( [48]. However, our analysis in fibroblasts
does not show an elevation of phosphorylation at Tyr$*( in io.
Increased tyrosine phosphorylation of FAK at Tyr$*( could
result in increased recruitment of Src, but our results suggest that
FAK6.7 does not exhibit increased Src binding in io. The
discrepancy between published results and the results obtained
in the present study may be due to the different cell types and
expression systems used or the use of different Tyr$*( phospho-
specific antibodies. In the light of our observations, the
mechanism of activation of FAK6.7 still remains to be solved.
Src plays an important role in biochemical signalling via FAK.
Src can bind autophosphorylated FAK and phosphorylate
activation-loop residues to further promote the activity of FAK
[3]. In addition, recruitment of Src into a complex with FAK may
direct phosphorylation of paxillin and tensin in io by Src [45].
These observations raise the question of the role Src plays
in signalling by SuperFAK and FAK6.7. Experiments using
phosphospecific antibodies and GST fusion proteins indicate that
there was no significant change in the level of phosphorylation of
Tyr$*( of the activated FAK mutants compared with wild-type
FAK. Further co-immunoprecipitation experiments reveal no
difference in the association of Fyn with wild-type FAK or the
activated mutants. Similarly, experiments using a Src inhibitor in
FAK kinase assays also suggest that the increase in catalytic
activity of SuperFAK is not due to increased association with Src
kinases. These observations suggest that enhanced signalling by
SuperFAK and FAK6.7 is not due to increased recruitment of
Src kinases. A FAK-dependent mechanism of Src activation has
been proposed [7,10]. However, experiments using Src phospho-
specific antibodies demonstrate that SuperFAK and FAK6.7
activate Src in io to the same extent as wild-type FAK. Thus
the enhanced effects of SuperFAK and FAK6.7 on downstream
signalling might be independent of Src. Furthermore, from these
studies it seems likely that paxillin and tensin are serving as
direct substrates for SuperFAK and FAK6.7. In contrast, expres-
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sion of SuperFAK or FAK6.7 did not result in elevated tyrosine
phosphorylation of p130cas. This observation is consistent with
the hypothesis that Src is the major kinase responsible for
tyrosine phosphorylation of p130cas [49,50].
One interesting observation was the apparent increase in
phosphorylation of Tyr*#& in SuperFAK relative to wild-type
FAK and FAK6.7. Src has been shown to be the kinase
responsible for phosphorylation of Tyr*#& ([12], but see [12a]).
However, since there is no difference in the association of FAK
and SuperFAK with Src family kinases, the mechanism leading
to phosphorylation of this site is unclear. Since phosphorylation
of Tyr*#& creates a Grb2-binding site linking FAK with the
MAPK cascade [51] and SuperFAK exhibits elevated levels of
phosphorylation at Tyr*#&, it was anticipated that SuperFAK
might induce enhanced activation of ERK. However, no sig-
nificant effect of SuperFAK upon adhesion-mediated or serum-
mediated ERK activation was observed in CE cells (results not
shown).
In our studies, the catalytic activity of SuperFAK and FAK6.7
was reduced when cells were held in suspension. However, in the
absence of an adhesion signal, SuperFAK and FAK6.7 still
displayed much higher kinase activity in itro compared with
wild-type FAK. Thus the kinase activity of SuperFAK and
FAK6.7 is only partially regulated by adhesion. These obser-
vations suggest that the mutants may not be constitutively
active, since they still require a cell-adhesion stimulus for max-
imal activation. Nevertheless, these mutants exhibit higher
enzymic activity compared with wild-type FAK. Although the
catalytic activity of SuperFAK and FAK6.7 remained high in
the absence of an adhesion signal, tyrosine phosphorylation of
downstream effectors did not occur in cells in suspension. These
observations indicate that the high catalytic activity of SuperFAK
and FAK6.7 is insufficient to induce substrate phosphorylation
in suspended cells. There are a number of possible explanations
for this observation. The absence of FAK substrate phosphoryl-
ation could be attributed to the action of cellular phosphatases,
which are more active, or have increased access to substrates,
when cells are in suspension. Alternatively, the proximity of the
activated FAK mutants to its substrates represents another
potential method of regulation. The assembly of proteins into
focal adhesions may be required not only for the efficient acti-
vation of FAK, but also for the clustering of FAK with its sub-
strates to promote their phosphorylation and the transmission
of FAK downstream signals.
Several FAK-binding partners have been implicated in media-
ting FAK-dependent cell motility, including Src family kinases
and PI 3-kinase [6,19]. Src kinases are likely to phosphorylate
downstream substrates to regulate motility, and one important
substrate implicated in cell motility is p130cas [20,52]. A FAK
mutant that cannot bind p130cas or induce its tyrosine phos-
phorylation is defective for induction of motility, implicating
p130cas in the regulation of motility by FAK [20]. It may
therefore be noteworthy that the FAK and SuperFAK do not
induce p130cas tyrosine phosphorylation, yet do promote cell
motility. FAK may utilize different signalling pathways to control
cell motility in different cell types. Further experimentation is
required to test this hypothesis.
The characterization of SuperFAK and FAK6.7 has demon-
strated the ability of these constructs to increase FAK-mediated
signals. Other membrane-bound constitutively activated FAK
constructs, CD2FAK and myrFAK, have been described
[28,29]. The best characterized of these FAK variants, CD2FAK,
exhibits biochemical properties different from those of
SuperFAK. First, its expression does not promote dramatic
increases of tyrosine phosphorylation of substrates in adherent
cells [23,50]. Secondly, in suspended cells expressing CD2FAK,
the tyrosine phosphorylation of paxillin and p130cas are sustained
[23,50]. Presumably, constitutive CD2FAK and MyrFAK sig-
nalling can be explained by their constitutive association with
the membrane and membrane-bound proteins such as Src. This
contrasts with the hyperactive signalling generated by SuperFAK
and FAK6.7 in response to normal physiological stimuli. In this
regard, SuperFAK may better mimic pathological situations
exhibiting overexpression of FAK. In different scenarios, the
membrane-bound chimaeras and SuperFAK may be utilized to
study the role of aberrant FAK signalling, alone or in com-
bination with other signalling partners, in the development of
human disease.
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